Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients

Table 1 Clinical and laboratory features of patients at first biopsy

Variables	Values
Number of patients	112
Age in years (mean ± SD)	46.9 ± 12.3
Gender (Male/Female)	65/47 (58%/42%)
Age at infection in years (mean ± SD)	25.8 ± 13.1
Route of infection
Blood transfusion	52/112 (46.4%)
Illegal drug use	13/112 (11.6%)
Other known routes	28/112 (25.0%)
Unknown	19/112 (17.0%)
Duration of infection in years (mean ± SD)	22.7 ± 10.8
Laboratory
Alanine aminotransferase (× UNL)	2.96 ± 2.43
Aspartate aminotransferase (× UNL)	1.74 ± 1.16
Gamma-glutamyltranspeptidase (× UNL)	1.28 ± 0.97
Serum albumin (mg/dL)	4.32 ± 0.51
Prothrombin activity (%)	90.2 ± 9.9
Platelet count (/mm3)	216 510 ± 68 088
Genotyping of HCV
1	73/105 (69.5%)
Non-1	31/105 (29.5%)
Indeterminate	1/105 (0.9%)
Liver Histopathology
Lymphoid aggregates	54/112 (48.2%)
Ductal injury	13/112 (11.6%)
Steatosis	58/112 (51.8%)
Siderosis	20/112 (18.0%)
IFN Receptors	79/110 (71.8%)
Fibrosis (METAVIR scoring system)
F0	19/112 (17.0%)
F1	41/112 (36.6%)
F2	25/112 (22.3%)
F3	6/112 (5.4%)
F4	21/112 (18.8%)
Histological Activity (METAVIR scoring system)
A0	27/112 (24.1%)
A1	53/112 (47.3%)
A2	24/112 (21.4%)
A3	8/112 (7.1%)
Treatment
Non-treated	33/112 (29.5%)
Treatment responders	23/112 (20.5%)
Treatment non-responders	56/112 (50.0%)

UNL: Upper normal limit.